Heart Failure Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy

  • ID: 4649627
  • Report
  • Region: Asia Pacific
  • 123 Pages
  • GBI Research
1 of 5

FEATURED COMPANIES

  • Bayer
  • Cynokinetics
  • Les Laboratoires Servier
  • Merck & Co.
  • Novartis
  • Procoralan
  • MORE

Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality. There are more than 26 million people with HF globally and this is increasing because of the rapidly aging population. HF is a major global healthcare problem as the number of HF patients is increasing. It has the greatest negative impact on quality of life compared with other major chronic disease, such as diabetes, arthritis, and hypertension.

HF has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles. Increasing risk factors will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth. Despite therapeutic advances, the morbidity and mortality associated with HF continues to be considerable, particularly in elderly patients.

In fact, most hospitalizations and deaths attributable to HF occur in people aged above 65. About half of all patients diagnosed with HF die within five years and the five-year survival rate is lower than that associated with other malignancies. The poor long-term prognosis associated with HF has created a pressing need for improved therapeutic options. The marketed products landscape comprises a wide range of treatment options, including ARN-targeted therapy, ACE inhibitors, ATR blockers, If channel inhibitor, beta blockers, MRAs and diuretics.

In the current market, chronic HF-REF patients can be treated with Entresto, Procoralan, ACE inhibitors, ATR blockers and beta blockers, while patients with acute HF can be prescribed therapies such as carperitide, diuretics and isosorbide dinitrate. However, significant unmet need remains for products that can treat HF-PEF patients and evidence-based therapy for acute HF. Entresto is in the pipeline for HF-PEF patients, and omecamtiv mecarbil and vericiguat are currently in Phase III development for post-acute patients.

Scope

  • The HF Asia-Pacific market will be valued at $1,435.9m in 2024, growing from $733.7m in 2017 at a CAGR of 10.1%.
  • How would the approval of Entresto to treat HF-PEF patients affect the competitive landscape, with no therapy currently available to address this patient subset?
  • The HF market is crowded with cheap, generic, “me-too” drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the HF market?
  • The pipeline for HF therapies is quite diverse with a range of molecule types and molecular targets.
  • Which molecular targets appear most frequently in the pipeline?
  • How have the late-stage therapies performed in clinical trials?
  • The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfill these unmet needs of the market?
  • The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
  • How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
  • How could changes in risk factors such as population age, CVD and lifestyle influence the market?
  • Various drivers and barriers will influence the market over the forecast period.
  • Licensing deals are the most common form of strategic alliance in HF, with total deal values ranging from under $0.072m to over $1000m.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?

Reasons to buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the HF market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the HF pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict HF market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the HF deals landscape by analyzing trends in licensing and co-development deals.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer
  • Cynokinetics
  • Les Laboratoires Servier
  • Merck & Co.
  • Novartis
  • Procoralan
  • MORE

1 Table of Contents

2 Introduction

2.1 Disease Introduction 
2.2 Epidemiology 
2.3 Symptoms 
2.4 Etiology and Pathophysiology 
    2.4.1 Pathophysiology 
2.5 Diagnosis 
    2.5.1 Diagnostic Algorithm for Chronic HF 
    2.5.2 Diagnostic Algorithm for Acute HF 
2.6 Disease Classification 
    2.6.1 Co-morbidities and Complications 
2.7 Prognosis 
2.8 Treatment Options and Treatment Algorithm 
    2.8.1 Treatment Options 
    2.8.2 Treatment Algorithm 
    2.8.3 Non-pharmacological Treatments 

3 Marketed Products

3.1 Overview 
    3.1.1 Entresto (sacubitril plus valsartan) - Novartis 
    3.1.2 Procoralan (ivabradine) - Les Laboratoires Servier 
    3.1.3 Angiotensin-Converting Enzyme Inhibitors 
    3.1.4 Angiotensin Receptor Blockers 
    3.1.5 Diuretics 
    3.1.6 Beta Blockers 
    3.1.7 Mineralocorticoid Receptor Antagonists 
    3.1.8 Digoxin 
3.2 Comparative Efficacy and Safety of Marketed Products 

4 Pipeline Analysis

4.1 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 
4.2 Pipeline by Molecular Target 
4.3 Promising Pipeline Candidates 
    4.3.1 Omecamtiv mecarbil (CK-1827452/AMG-423) - Cynokinetics 
    4.3.2 Vericiguat - Bayer/Merck & Co. 
4.4 Comparative Efficacy and Safety of Pipeline Products 
4.5 Product Competitiveness Framework 

5 Clinical Trial Analysis

5.1 Failure Rate 
    5.1.1 Overall Failure Rate 
    5.1.2 Failure Rate by Phase and Molecule Type 
    5.1.3 Failure Rate by Phase and Molecular Target 
5.2 Clinical Trial Size 
    5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 
    5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 
    5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 
    5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 
5.3 Clinical Trial Duration 
    5.3.1 Trial Duration by Molecule Type and Stage of Development 
    5.3.2 Trial Duration by Molecular Target and Stage of Development 
5.4 Summary of Clinical Trial Metrics 

6 Multi-scenario Forecast

6.1 Geographical Markets 
6.2 Asia-Pacific Market 
6.3 India 
    6.3.1 Treatment Usage Patterns 
    6.3.2 Annual Cost of Therapy 
    6.3.3 Market Size 
6.4 China 
    6.4.1 Treatment Usage Patterns 
    6.4.2 Annual Cost of Therapy 
    6.4.3 Market Size 
6.5 Australia 
    6.5.1 Treatment Usage Patterns 
    6.5.2 Annual Cost of Therapy 
    6.5.3 Market Size 
6.6 South Korea 
    6.6.1 Treatment Usage Patterns 
    6.6.2 Annual Cost of Therapy 
    6.6.3 Market Size 
6.7 Japan 
    6.7.1 Treatment Usage Patterns 
    6.7.2 Annual Cost of Therapy 
    6.7.3 Market Size 

7 Drivers and Barriers

7.1 Drivers 
    7.1.1 Rising Prevalence and Growing Awareness of the Disease to Drive Market Growth 
    7.1.2 Promising Pipeline Products that Target Unmet Needs for HF 
    7.1.3 Increasing Awareness and Diversified Healthcare Reform to Boost Market Growth 
    7.1.4 Launch of Entresto and its Label Expansion will Drive Market Growth 
7.2 Barriers 
    7.2.1 Market Access for New Therapies as well as Crowded and Cheap Generic Market 
    7.2.2 Lack of Development of Acute HF Pipeline Products 
    7.2.3 Reluctance of Cardiologists to Adopt New Therapies 

8 Deals and Strategic Consolidations

8.1 Licensing Deals 
    8.1.1 Deals by Region and Value 
    8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 
    8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 
    8.1.4 Key Licensing Deals 
8.2 Co-development Deals 
    8.2.1 Deals by Region and Value 
    8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 
    8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 
    8.2.4 Key Co-development Deals 

9 Appendix

9.1 All Pipeline Drugs by Stage of Development 
    9.1.1 Discovery 
    9.1.2 Preclinical 
    9.1.3 IND/CTA-filed 
    9.1.4 Phase I 
    9.1.5 Phase II 
    9.1.6 Phase III 
    9.1.7 Pre-registration 
9.2 Summary of Multi-scenario Market Forecasts to 2024 
    9.2.1 Asia-Pacific 
    9.2.2 India 
    9.2.3 China 
    9.2.4 Australia 
    9.2.5 South Korea 
    9.2.6 Japan 
9.3 Bibliography 
9.4 Abbreviations 
9.5 Research Methodology 
    9.5.1 Secondary Research 
    9.5.2 Marketed Product Profiles 
    9.5.3 Late-Stage Pipeline Candidates 
    9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 
    9.5.5 Product Competitiveness Framework 
    9.5.6 Pipeline Analysis 
    9.5.7 Forecasting Model 
    9.5.8 Deals Data Analysis 
9.6 Contact Us 
9.7 Disclaimer 

1.1 List of Tables

Table 1: Heart Failure Therapeutics Market, Symptoms 
Table 2: Heart Failure Therapeutics Market, New York Heart Association Classification of HF 
Table 3: Heart Failure Therapeutics Market, Etiologies of HF 
Table 4: Heart Failure Therapeutics Market, Key Diagnostic and Prognostic Biomarkers in HF 
Table 5: Heart Failure Therapeutics Market, Definition of HF with Preserved (HFpEF), Mid-range (HFmrEF) and Reduced Ejection Fraction (HFrEF) 
Table 6: Heart Failure Therapeutics Market, Importance of Co-morbidities in Patients with HF 
Table 7: Heart Failure Therapeutics Market, Drugs Used in HF with Reduced Left Ventricular Ejection Fraction 
Table 8: Heart Failure Therapeutics Market, Global, Licensing Deals Value, 2007-2018 
Table 9: Heart Failure Therapeutics Market, Global, Co-development Deals Value, 2007-2018 
Table 10: Heart Failure Therapeutics Market, Global, All Pipeline Products, Discovery, 2018 
Table 11: Heart Failure Therapeutics Market, Global, All Pipeline Products, Preclinical, 2018 
Table 12: Heart Failure Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2018 
Table 13: Heart Failure Therapeutics Market, Global, All Pipeline Products, Phase I, 2018 
Table 14: Heart Failure Therapeutics Market, Global, All Pipeline Products, Phase II, 2018 
Table 15: Heart Failure Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 
Table 16: Heart Failure Therapeutics Market, Global, All Pipeline Products, Phase III, 2018 
Table 17: Heart Failure Therapeutics Market, APAC, Market Forecast, 2017-2024 
Table 18: Heart Failure Therapeutics Market, India, Market Forecast, 2017-2024 
Table 19: Heart Failure Therapeutics Market, China, Market Forecast, 2017-2024 
Table 20: Heart Failure Therapeutics Market, Australia, Market Forecast, 2017-2024 
Table 21: Heart Failure Therapeutics Market, South Korea, Market Forecast, 2017-2024 
Table 22: Heart Failure Therapeutics Market, Japan, Market Forecast, 2017-2024 

1.2 List of Figures

Figure 1: Heart Failure Therapeutics Market, Western Australia, Prevalence of HF Due to Risk factors (%) 
Figure 2: Heart Failure Therapeutics Market, Types of HF 
Figure 3: Heart Failure Therapeutics Market, Pathophysiology of HF 
Figure 4: Heart Failure Therapeutics Market, Diagnostic Algorithm for Chronic HF 
Figure 5: Heart Failure Therapeutics Market, Diagnosis Algorithm of Acute HF 
Figure 6: Heart Failure Therapeutics Market, Stages of HF 
Figure 7: Heart Failure Therapeutics Market, Approach to Management of HF with Reduced Ejection Fraction 
Figure 8: Heart Failure Therapeutics Market, Management of Patients with Acute HF Based on Clinical Profile During an Early Phase 
Figure 9: Heart Failure Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Heart Failure Treatment, 2018 
Figure 10: Heart Failure Therapeutics Market, Global, Pipeline, 2018 
Figure 11: Heart Failure Therapeutics Market, Global, Pipeline by Molecular Target, 2018 
Figure 12: Heart Failure Therapeutics Market, APAC, Omecamtiv Mecarbil Forecast ($m), 2022-2024 
Figure 13: Heart Failure Therapeutics Market, APAC, Vericiguat Forecast ($m), 2021-2024 
Figure 14: Heart Failure Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for Heart Failure Treatment 
Figure 15: Heart Failure Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2007-2017 
Figure 16: Heart Failure Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2007-2017 
Figure 17: Heart Failure Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2007-2017 
Figure 18: Heart Failure Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2007-2017 
Figure 19: Heart Failure Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2007-2017 
Figure 20: Heart Failure Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2007-2017 
Figure 21: Heart Failure Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2007-2017 
Figure 22: Heart Failure Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2007-2017 
Figure 23 Heart Failure Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2007-2017 
Figure 24: Heart Failure Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 
Figure 25: Heart Failure Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 
Figure 26: Heart Failure Therapeutics Market, APAC, Treatment Patterns (‘000), 2017-2024 
Figure 27: Heart Failure Therapeutics Market, APAC, Market Size ($m), 2017-2024 
Figure 28: Heart Failure Therapeutics Market, India, Treatment Patterns (‘000), 2017-2024 
Figure 29: Heart Failure Therapeutics Market, India, Annual Cost of Therapy ($), 2017-2024 
Figure 30: Heart Failure Therapeutics Market, India, Market Size ($m), 2017-2024 
Figure 31: Heart Failure Therapeutics Market, China, Treatment Patterns (‘000), 2017-2024 
Figure 32: Heart Failure Therapeutics Market, China, Annual Cost of Therapy ($), 2017-2024 
Figure 33: Heart Failure Therapeutics Market, China, Market Size ($m), 2017-2024 
Figure 34: Heart Failure Therapeutics Market, Australia, Treatment Patterns (‘000), 2017-2024 
Figure 35: Heart Failure Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017-2024 
Figure 36: Heart Failure Therapeutics Market, Australia, Market Size ($m), 2017-2024 
Figure 37: Heart Failure Therapeutics Market, South Korea, Treatment Patterns (‘000), 2017-2024 
Figure 38: Heart Failure Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017-2024 
Figure 39: Heart Failure Therapeutics Market, South Korea, Market Size ($m), 2017-2024 
Figure 40: Heart Failure Therapeutics Market, Japan, Treatment Patterns (‘000), 2017-2024 
Figure 41: Heart Failure Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017-2024 
Figure 42: Heart Failure Therapeutics Market, Japan, Market Size ($m), 2017-2024 
Figure 43: Heart Failure Therapeutics Market, Global, Licensing Deals by Region and Value, 2007-2018 
Figure 44: Herat Failure Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 
Figure 45: Heart Failure Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 
Figure 46: Heart Failure Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007-2018 
Figure 47: Heart Failure Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007-2018 
Figure 48: Heart Failure Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2007-2018 
Figure 49: Heart Failure Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007-2018 
Figure 50: Heart Failure Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007-2018 
Figure 51: Heart Failure Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007-2018 
Figure 52: Heart Failure Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007-2018

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Novartis
  • Les Laboratoires Servier
  • Procoralan
  • Bayer
  • Merck & Co.
  • Cynokinetics
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll